A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity
Recruiting
Phase 3
Interventional Study
Obesity
Overweight and/or Obesity
Overweight
Treatment Of Obesity
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 660 (estimated)
- Sponsor
- Pfizer · Industry
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The purpose of this study is to learn about the safety and effectiveness of berobenatide in adults with overweight or obesity who have already lost weight while taking semaglutide or tirzepatide. The study does not include people with diabetes. Participants will be in the study for about 11 months.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Aged ≥18 years.
* Currently taking semaglutide or tirzepatide for obesity management.
Exclusion Criteria:
* Diagnosis of any form of diabetes.
* History of acute or chronic pancreatitis.
* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine …
Contacts